Advertisement


Andreas Obermair, MD, on Treating Endometrial Adenocarcinoma With a Levonorgestrel Intrauterine Device

SGO 2021 Virtual Annual Meeting on Womens Cancer

Advertisement

Andreas Obermair, MD, of the University of Queensland and Queensland Centre for Gynaecological Cancer Research, discusses data on a hormonal IUD used to treat women with the precursor lesion endometrial hyperplasia with atypia (EHA) and those with stage I endometrial adenocarcinoma (EAC). At 6 months, the data showed a complete pathologic response in 82% of patients with EHA and in 43% of those with EAC (ID# 10244).



Related Videos

Gynecologic Cancers

Rebecca S. Kristeleit, MD, PhD, on Relapsed Ovarian Cancer: Rucaparib vs Chemotherapy

Rebecca S. Kristeleit, MD, PhD, of the University College London and UCL Cancer Institute, discusses efficacy and safety results from the phase III ARIEL4 study, which showed that rucaparib improved progression-free survival vs standard-of-care chemotherapy in patients with BRCA-mutated, platinum-resistant, or platinum-sensitive relapsed ovarian cancer (ID #10191).

Gynecologic Cancers
Survivorship
Symptom Management

Lauren Thomaier, MD, on Predicting Chemotherapy-Induced Peripheral Neuropathy in Gynecologic Cancer Survivors

Lauren Thomaier, MD, of the University of Minnesota, discusses the genetic variants found to be associated with an increase in chemotherapy-induced neuropathy symptoms in a cohort of gynecologic cancer survivors. Combining these variants with clinical characteristics may provide an important treatment tool (ID# 10253).

Gynecologic Cancers

Morcos N. Nakhla, MS, on Surgical Outcomes for Frail Patients With Ovarian Cancer

Morcos N. Nakhla, MS, a second-year student at the David Geffen School of Medicine at UCLA, discusses data showing that a higher surgical volume is associated with better outcomes for frail patients undergoing surgery for ovarian cancer. Over the 12-year study period, mortality decreased for all women with ovarian cancer, despite a concurrent increase in frail patients (ID #10209).

Gynecologic Cancers
Immunotherapy

Amir A. Jazaeri, MD, on Metastatic Cervical Cancer: The Role of Immunotherapy

Amir A. Jazaeri, MD, of The University of Texas MD Anderson Cancer Center, discusses data on the safety and efficacy of adoptive cell transfer using autologous tumor-infiltrating lymphocytes (LN-145) to treat patients with recurrent, metastatic, or persistent cervical carcinoma whose tumors have progressed on prior systemic therapy (ID # 10224).

Gynecologic Cancers
Pain Management

Brittany A. Davidson, MD, on a Model to Predict the Need for Opioids After Gynecologic Surgery

Brittany A. Davidson, MD, of Duke University, discusses the development and validation of the GO-POP model (Gynecologic Oncology Predictor of Postoperative opioid use), an individualized patient-centered predictive tool designed to help avoid overprescribing pain medications (ID# 10253).

Advertisement

Advertisement



Advertisement